You are viewing the site in preview mode

Skip to main content

Table 5 Costs, effects and incremental cost-effectiveness ratios (ICER) for different scenarios. Data are expressed as mean value per infant

From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Scenario   Costs QALYs Incremental ICER
Costs QALYs
Base case Prophylaxis 12,848 EUR 17.82 −3833 EUR 0.06 Dominance
No Prophylaxis 16,681 EUR 17.75
Time horizon = 1y Prophylaxis 8834 EUR 0.88 − 1481 EUR 0.01 Dominance
No Prophylaxis 10,315 EUR 0.88
Time horizon = 5y Prophylaxis 9341 EUR 3.76 − 1868 EUR 0.01 Dominance
No Prophylaxis 11,209 EUR 3.74
Time horizon = 10y Prophylaxis 9964 EUR 6.84 − 2292 EUR 0.02 Dominance
No Prophylaxis 12,255 EUR 6.81
No asthma Prophylaxis 11,378 EUR 17.92 − 3563 EUR 0.04 Dominance
No Prophylaxis 14,941 EUR 17.88
No RSV-death Prophylaxis 12,962 EUR 17.85 − 3925 EUR 0.03 Dominance
No Prophylaxis 16,887 EUR 17.82
No RSV-death, no asthma Prophylaxis 11,477 EUR 17.95 − 3643 EUR 0.01 Dominance
No Prophylaxis 15,120 EUR 17.94
No delayed heart surgeries Prophylaxis 10,304 EUR 17.83 −1751 EUR 0.05 Dominance
No Prophylaxis 12,055 EUR 17.78
Mortality = general population Prophylaxis 15,337 EUR 27.30 − 5137 EUR 0.10 Dominance
No Prophylaxis 20,474 EUR 27.21
No productivity loss Prophylaxis 10,236 EUR 17.82 − 1667 EUR 0.06 Dominance
No Prophylaxis 11,903 EUR 17.75
Productivity loss of both parents Prophylaxis 12,916 EUR 17.82 − 3916 EUR 0.06 Dominance
No Prophylaxis 16,832 EUR 17.75
  1. ICER incremental cost-effectiveness ratio, RSV Respiratory syncytial virus, QALY quality-adjusted life year, y years
Back to article page

Journal of Congenital Cardiology

ISSN: 2056-7251

Contact us

\